Drug intelligence / Profile preview

rutin + ascorbic acid

Development stage: Unknown
Lead developer: Ain Shams University
Modality: Small Molecules
Administration: Oral

Overview

Rutin + ascorbic acid is a combination of the bioflavonoid rutin and the antioxidant vitamin C (ascorbic acid). It is currently being investigated by Ain Shams University in a Phase 2 clinical trial for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD). The combination is hypothesized to exert synergistic antioxidant and anti-inflammatory effects, thereby reducing oxidative stress markers and hepatic steatosis. Rutin acts as a scavenger of free radicals and may inhibit lipid peroxidation, while ascorbic acid serves as a primary antioxidant that regenerates other antioxidants and directly neutralizes reactive oxygen species. The treatment is administered orally as a tablet.

Other names: Rutin + Vitamin CVitamin P + Vitamin C

Beyond the preview

Go deeper on rutin + ascorbic acid.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on rutin + ascorbic acid.

Explore the full profile